Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BCYC 
Bicycle Therapeutics Ltd (BCYC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: BCYC (1-star) is a SELL. SELL since 3 days. Simulated Profits (-12.85%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $21.28
1 Year Target Price $21.28
| 5 | Strong Buy |
| 5 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.42% | Avg. Invested days 24 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 428.00M USD | Price to earnings Ratio - | 1Y Target Price 21.28 |
Price to earnings Ratio - | 1Y Target Price 21.28 | ||
Volume (30-day avg) 13 | Beta 1.47 | 52 Weeks Range 6.10 - 25.39 | Updated Date 11/5/2025 |
52 Weeks Range 6.10 - 25.39 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.62 |
Earnings Date
Report Date 2025-10-29 | When Before Market | Estimate -0.9708 | Actual -0.85 |
Profitability
Profit Margin - | Operating Margin (TTM) -558.64% |
Management Effectiveness
Return on Assets (TTM) -19.07% | Return on Equity (TTM) -31.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -123069462 | Price to Sales(TTM) 15.1 |
Enterprise Value -123069462 | Price to Sales(TTM) 15.1 | ||
Enterprise Value to Revenue 21.22 | Enterprise Value to EBITDA -2.14 | Shares Outstanding 49929952 | Shares Floating 1884365 |
Shares Outstanding 49929952 | Shares Floating 1884365 | ||
Percent Insiders 1.4 | Percent Institutions 87.65 |
Upturn AI SWOT
Bicycle Therapeutics Ltd
Company Overview
History and Background
Bicycle Therapeutics Ltd. was founded in 2009 and is headquartered in Cambridge, UK. It is a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycleu00ae) technology. The company focuses on discovering and developing Bicycleu00ae-based therapeutics for diseases with high unmet medical needs.
Core Business Areas
- Bicycle Toxin Conjugates (BTCs): Development of targeted therapeutics by conjugating Bicycle peptides with toxins to selectively kill cancer cells.
- Bicycle Radio conjugates (BRCs): Development of targeted radioisotope therapeutics based on Bicycle peptides for tumor targeting
- Bicycle Immune Cell Agonists (BICAs): Development of therapeutics that leverage the Bicycle platform to activate immune cells and enhance anti-tumor immunity.
Leadership and Structure
The leadership team includes Kevin Lee, PhD (CEO) and various senior vice presidents overseeing research, development, and operations. The company operates with a functional organizational structure with specialized teams focused on research, clinical development, and commercial strategy.
Top Products and Market Share
Key Offerings
- BT8009: A Bicycle Toxin Conjugate (BTC) targeting Nectin-4, being developed for the treatment of advanced solid tumors. Currently in Phase I/II clinical trials. Competitors include companies developing antibody-drug conjugates targeting Nectin-4, such as Astellas and Seagen with enfortumab vedotin (Padcev).
- BT5500: A Bicycle Toxin Conjugate (BTC) targeting EphA2, being developed for solid tumors. Currently in Phase I clinical trials. Competitors include companies developing other EphA2-targeting therapies.
- BT7480: A Bicycle T cell engager targeting Nectin-4 and CD137 for solid tumors. Currently in Phase I/II clinical trials. Competitors include other companies developing T cell engagers.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, rapid technological advancements, and high regulatory hurdles. The oncology segment is particularly dynamic, driven by the continuous need for innovative therapies to treat cancer.
Positioning
Bicycle Therapeutics is positioned as an innovative company leveraging its proprietary Bicycleu00ae technology to develop novel therapies targeting cancer and other diseases. Its competitive advantage lies in the unique properties of Bicycle peptides, which offer high affinity, specificity, and rapid tissue penetration.
Total Addressable Market (TAM)
The oncology market is expected to reach hundreds of billions of dollars. Bicycle Therapeutics aims to capture a portion of this market with its targeted therapies. They are positioned to address unmet needs in solid tumors where the TAM is substantial.
Upturn SWOT Analysis
Strengths
- Proprietary Bicycleu00ae technology platform
- Targeted therapies with potential for improved efficacy and safety
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Clinical trial risks and uncertainties
- Reliance on partnerships for development and commercialization
- Limited financial resources compared to larger pharmaceutical companies
- Early stage development pipeline
Opportunities
- Expansion of the Bicycleu00ae technology platform to new therapeutic areas
- Strategic collaborations with pharmaceutical companies
- Positive clinical trial results leading to regulatory approvals
- Addressing unmet medical needs in oncology and other diseases
Threats
- Competition from established pharmaceutical companies
- Failure to achieve positive clinical trial results
- Regulatory hurdles and delays
- Changes in the healthcare landscape and reimbursement policies
Competitors and Market Share
Key Competitors
- ASTS
- MRTX
- IMVT
Competitive Landscape
Bicycle Therapeutics competes with other biopharmaceutical companies developing targeted therapies for cancer. Its Bicycleu00ae technology offers a differentiated approach with the potential for improved efficacy and safety, but it faces competition from established modalities such as antibody-drug conjugates and small molecule inhibitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by the advancement of its Bicycleu00ae platform and pipeline, achieving key milestones in clinical trials, and securing partnerships with larger pharmaceutical companies.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of its therapies. Analyst estimates vary, but generally project revenue growth based on potential product launches.
Recent Initiatives: Recent initiatives include advancing clinical trials for BT8009 and BT5500, expanding its pipeline with new Bicycleu00ae-based therapies, and strengthening partnerships.
Summary
Bicycle Therapeutics is a clinical-stage company with a novel drug discovery platform. The company has seen steady growth and is advancing multiple Bicycle-based therapeutics through clinical trials. Clinical trial results and partnerships will heavily influence the future trajectory of the company. Challenges the company faces includes raising capital and succeeding in trials.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
- Third party aggregators like Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bicycle Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-05-23 | CEO & Executive Director Dr. Kevin Lee M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 305 | |
Full time employees 305 | |||
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.